Literature DB >> 8873386

Recombinant, octavalent group A streptococcal M protein vaccine.

J B Dale1, M Simmons, E C Chiang, E Y Chiang.   

Abstract

One of the major obstacles to the development of group A streptococcal M protein vaccines is the multiplicity of M serotypes expressed by these organisms. In this study, we have constructed a recombinant, hybrid M protein that contains type-specific aminoterminal fragments of eight different M proteins. We show that the purified hybrid recombinant protein is immunogenic in rabbits and evokes antibodies that react with native M proteins from the respective streptococcal serotypes. In addition, the immune sera evoked by the octavalent protein opsonized six of the eight serotypes of streptococci, indicating that the majority of the M protein fragments contained protective epitopes that retained their native conformations in the hybrid protein. None of the antisera raised against the octavalent protein crossreacted with human heart tissue. These studies indicate that multivalent, hybrid M proteins may be used to elicit broadly protective immune responses against multiple serotypes of group A streptococci.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873386     DOI: 10.1016/0264-410x(96)00050-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Multilocus sequence typing of Streptococcus pyogenes and the relationships between emm type and clone.

Authors:  M C Enright; B G Spratt; A Kalia; J H Cross; D E Bessen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.

Authors:  E R Brandt; T Teh; W A Relf; R I Hobb; M F Good
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

4.  Immunogenicity of a 26-valent group A streptococcal vaccine.

Authors:  Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

5.  New protective antigen of group A streptococci.

Authors:  J B Dale; E Y Chiang; S Liu; H S Courtney; D L Hasty
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

6.  Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.

Authors:  Mary A Hall; Steven D Stroop; Mary C Hu; Michael A Walls; Mark A Reddish; David S Burt; George H Lowell; James B Dale
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

7.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

8.  Group A streptococcal genotypes from pediatric throat isolates in Rome, Italy.

Authors:  G Dicuonzo; G Gherardi; G Lorino; S Angeletti; M De Cesaris; E Fiscarelli; D E Bessen; B Beall
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

9.  Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes.

Authors:  James B Dale; Thomas Penfound; Edna Y Chiang; Valerie Long; Stanford T Shulman; Bernard Beall
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

10.  Serum opacity factor (SOF) of Streptococcus pyogenes evokes antibodies that opsonize homologous and heterologous SOF-positive serotypes of group A streptococci.

Authors:  Harry S Courtney; David L Hasty; James B Dale
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.